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Abstract Protein kinase D (PKD)/protein kinase CW (PKCW),
a serine/threonine protein kinase with distinct structural and
enzymological properties, is rapidly activated in intact cells via
PKC. The amino-terminal region of PKD contains a cysteine-
rich domain (CRD) that directly binds phorbol esters with a high
affinity. Here, we show that treatment of transfected RBL 2H3
cells with phorbol 12,13-dibutyrate (PDB) induces a striking
CRD-dependent translocation of PKD from the cytosol to the
plasma membrane, as shown by real time visualization of a
functional green fluorescent protein (GFP)-PKD fusion protein.
A single amino acid substitution in the second cysteine-rich motif
of PKD (P287G) prevented PDB-induced membrane transloca-
tion but did not affect PKD activation. Our results indicate that
PKD translocation and activation are distinct processes that
operate in parallel to regulate the activity and localization of this
enzyme in intact cells.
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1. Introduction
Protein kinase C (PKC), a major target for the tumor pro-
moting phorbol esters, has been implicated in the signal trans-
duction of a wide range of biological responses, including
changes in cell morphology, di¡erentiation and proliferation
[1,2]. Molecular cloning has demonstrated the presence of
multiple related PKC isoforms [2^5], i.e. conventional PKCs
(K, L1, L2 and Q), novel PKCs (N, O, R and a) and atypical
PKCs (j and V), all of which possess a highly conserved cata-
lytic domain.
Protein kinase D (PKD)/PKCW is a serine/threonine protein
kinase with distinct structural, enzymological and regulatory
properties [6,7]. The catalytic domain of PKD is distantly
related to Ca2-regulated kinases and shows little similarity
to the highly conserved regions of the kinase subdomains of
the PKC family [8]. Consistent with this, PKD does not phos-
phorylate a variety of substrates utilized by PKCs, indicating
that PKD is a protein kinase with a distinct substrate-specif-
icity [6,9]. In contrast to all PKCs, the NH2-terminal region of
PKD contains a pleckstrin homology (PH) domain that reg-
ulates enzyme activity [10] and lacks a sequence with homol-
ogy to a typical PKC auto-inhibitory pseudosubstrate motif
[6]. In addition, the amino-terminal region of PKD contains a
tandem repeat of cysteine-rich, zinc ¢nger-like motifs [6,7]
that binds phorbol esters with high a⁄nity [6,11]. The two
motifs within this cysteine-rich domain (CRD) are not func-
tionally equivalent, however, with the second cysteine motif
acting as the major site for phorbol ester binding, both in
vitro and in vivo [11]. PKD and its human homologue
PKCW can be stimulated in vitro by either bioactive phorbol
esters or diacylglycerol (DAG) in the presence of phosphati-
dylserine [12,13], indicating that PKD/PKCW is a phorbol es-
ter/DAG-stimulated kinase.
In intact cells, PKD can be activated by treatment with
pharmacological agents, including phorbol esters, cell-perme-
ant DAGs and bryostatin 1, or by physiological stimuli that
elevate DAG levels, including neuropeptide agonists and
PDGF [10,12,14^17]. Several lines of evidence indicate that
PKD is activated by these agents through a novel PKC-de-
pendent signal transduction pathway [12,14,16] that is de-
pendent on the phosphorylation of two activation loop sites,
namely Ser-744 and Ser-748 [18]. Thus, PKC inhibitors (with
no direct activity towards PKD) prevent PKD phosphoryla-
tion and activation in response to phorbol esters and mito-
gens. Furthermore, the expression of constitutively activated
mutants of the novel PKCs O and R is su⁄cient to induce
PKD activation [12,19,20]. Recent results demonstrating that
PKCR can interact with the PH domain of PKD [19] also
indicate a direct link between PKCs and PKD.
In the present study, we examined whether direct binding of
phorbol esters to the CRD of PKD in vivo is necessary for
PKC-dependent PKD activation. We demonstrate that expo-
sure of intact cells to phorbol esters induces a striking CRD-
dependent translocation of PKD from the cytosol to the plas-
ma membrane, as shown by real time visualization of a func-
tional green £uorescent protein (GFP)-PKD molecule as well
as by biochemical fractionation. Using a translocation-im-
paired PKD mutant which contains a single amino acid sub-
stitution (P287G) in the second cysteine-rich motif, we show
that phorbol ester-induced translocation of PKD is not re-
quired for PKD activation. We conclude that translocation
and activation are distinct processes that operate in parallel
to regulate PKD in intact cells.
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2. Materials and methods
2.1. Cell culture
COS-7 cells were plated in 60 mm dishes at 3U105 cells/dish in
Dulbecco’s modi¢ed Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum and were used for transfection 24 h later.
Exponentially growing COS-7 cells, 40^60% con£uent, were trans-
fected with cDNA constructs using lipofectin (Life Technologies) as
previously described [9,12]. The mast cell line, RBL 2H3, was main-
tained in DMEM supplemented with 10% fetal bovine serum. RBL
2H3 cells (1.5U107 cells) were transfected with cDNA constructs by
electroporation (310 V, 960 WF), as previously described [21], seeded
onto sterile glass coverslips and allowed to recover overnight.
2.2. cDNA constructs
PKD expression constructs containing a point mutation within the
CRD (P287G) or a mutant lacking the entire CRD (vCRD) have
previously been described [11]. Chimeric fusion proteins between
GFP and PKD were generated by subcloning PKD constructs into
the EcoRI site of a pEF-plink2-GFPC3 expression vector. GFP con-
structs were veri¢ed by restriction enzyme analysis and sequencing.
Constitutively active PKCO and R constructs were generous gifts from
Dr P. Parker [22].
2.3. Biochemical fractionation assays
Cells were washed twice in ice-cold phosphate-bu¡ered saline (PBS)
and resuspended in isotonic bu¡er (25 mM Tris, pH 7.4, 250 mM
sucrose, 2.5 mM MgAc, 10 mM NaF, 5 mM EDTA, 5 mM EGTA,
1 mM dithiothreitol, 10 fg/ml aprotinin, 10 fg/ml leupeptin and 1 mM
4-(2P-aminoethyl)-benzenesulfonyl £uoride hydrochloride). Cells were
lysed by disruption using a 1 ml Dounce homogenizer and nuclei/
unbroken cells were pelleted by centrifugation at 800Ug for 1 min.
Cytosolic (soluble) and membrane (pellet) fractions were prepared
from the resulting homogenate by ultracentrifugation at 100 000Ug
for 20 min at 4‡C. Equal protein samples from each fraction were
extracted for 10 min in 5Usodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) sample bu¡er and analyzed by gel elec-
trophoresis, followed by transfer to Immobilon membranes at 100 V,
0.4 A, 4‡C for 4 h in a bu¡er containing 200 mM glycine, 25 mM Tris,
0.01% SDS and 20% methanol. Membranes were blotted with either
anti-PKD or anti-GFP antibodies and immunoreactive bands were
visualized by enhanced chemiluminescence (ECL).
2.4. Cell imaging
RBL 2H3 mast cells expressing GFP-PKD constructs and grown on
sterile glass coverslips were ¢xed in 4% paraformaldehyde for 30 min
at room temperature. Nuclear staining using propidium iodide was
carried out by permeabilization of cells in 0.1% Triton X-100, fol-
lowed by sequential incubation with 500 ng/ml RNAse A (37‡C, 10
min) and 0.1 Wg/ml propidium iodide (at room temperature for 10
min). Coverslips were washed in PBS after each stage and mounted
in 15 Wl Gelvatol (Leica, St. Louis, MO, USA) which was allowed to
set for at least 4 h. For live cell imaging, cells were incubated in
phenol-red free medium (supplemented with 20 mM HEPES bu¡er,
pH = 7.3) and placed inside a pre-warmed (37‡C) chamber under an
inverted confocal microscope. All confocal images were taken using a
Zeiss Axiovert-100M inverted confocal laser microscope. GFP £uo-
rescence was excited with an argon laser emitting at 488 nm and
images were acquired using a 63UNA1.4 oil immersion lens and Zeiss
LSM 510 software.
2.5. In vitro kinase assays
Cells were washed twice in ice-cold PBS and lysed in 50 mM Tris-
HCl, pH 7.4, 2 mM EGTA, 2 mM EDTA, 1 mM dithiothreitol, 10 fg/
ml aprotinin, 10 fg/ml leupeptin, 1 mM 4-(2P-aminoethyl)-benzenesul-
fonyl £uoride hydrochloride and 1% Triton X-100 (lysis bu¡er). PKD
was immunoprecipitated at 4‡C for 2 h with the PA-1 antiserum
(1:100 dilution), previously described [9]. Immunocomplexes were re-
covered with Protein A-agarose beads, washed twice in lysis bu¡er
and once in kinase bu¡er (30 mM Tris-HCl, pH 7.4, 10 mM MgCl2
and 1 mM dithiothreitol). PKD autophosphorylation was determined
by incubating immunocomplexes with 15 Wl kinase bu¡er containing
100 WM [Q-32P]ATP, ¢nal concentration. After incubation at 30‡C for
10 min, reactions were terminated by the addition of 2USDS-PAGE
sample bu¡er and analyzed by gel electrophoresis and autoradiogra-
phy. Exogenous substrate phosphorylation by PKD was measured by
the incorporation of radioactivity into syntide-2, as previously de-
scribed [6,9].
2.6. [3H]Phorbol 12,13-dibutyrate (PDB) binding assays
[3H]PDB binding to intact COS-7 cells was performed by incubat-
ing cells in DMEM containing 1 mg/ml bovine serum albumin and
20 nM [3H]PDB at 37‡C for 30 min [11]. The cells were then rapidly
washed with ice-cold PBS containing 1 mg/ml bovine serum albumin
and lysed with NaOH-SDS. Bound radioactivity was determined by
liquid scintillation counting. Non-speci¢c binding was determined in
the presence of 10 WM unlabelled PDB.
2.7. Materials
ECL reagents, [3H]PDB and [Q32P]ATP (370 MBq/ml) were from
Amersham International (UK). PDB was from Sigma and the
PKC inhibitors, GF 109203X and Ro 31-8220 were from LC Labo-
ratories. Protein A-agarose was from Boehringer Mannheim. All
other reagents were from standard suppliers or as indicated in the
text.
3. Results
3.1. Generation of biologically active GFP-PKD chimeric
fusion proteins
In order to examine PDB-induced translocation of PKD,
we generated chimeric fusion proteins between GFP from Ae-
quorea victoria and either the wild-type (WT) PKD (GFP-
PKD) or a PKD deletion mutant lacking the tandem repeat
of the cysteine-rich motifs which constitutes the DAG/phorbol
ester binding domain of PKD (GFP-PKD vCRD) (Fig. 1A).
GFP, which forms an independent 30 kDa domain with in-
herent £uorescence, has provided a valuable reporter molecule
in the cellular localization of multiple proteins [23], including
phorbol ester-regulated PKCs [24^26]. As shown in Fig. 1A,
the GFP-PKD molecule, when transiently expressed in either
COS-7 or RBL 2H3 cells, had the expected molecular mass
(140 kDa) and could easily be distinguished from the endog-
enous PKD (110 kDa) of RBL 2H3 cells, as shown by West-
ern blotting of whole cell lysates with either anti-PKD or anti-
GFP antibodies. The results presented in Fig. 1A also show
the expression of GFP-PKD vCRD.
Next, we veri¢ed that the GFP fusion protein GFP-PKD
displays biological properties similar to that of native PKD,
as judged by phorbol ester-mediated PKD activation and
phorbol ester binding. As shown in Fig. 1B, GFP-PKD, like
PKD, displayed a very low catalytic activity in resting trans-
fected COS-7 cells but could be markedly activated by treat-
ment of the intact cells with PDB. Similarly, COS-7 cells
transfected with either PKD or GFP-PKD showed an V9-
fold increase in speci¢c [3H]PDB binding as compared with
that obtained in COS-7 cells transfected with the vector alone
(Fig. 1C). No signi¢cant increase in speci¢c [3H]PDB binding
was detected in COS-7 cells expressing either PKD vCRD or
GFP-PKD vCRD (Fig. 1C), despite similar levels of expres-
sion of all the PKD constructs (results not shown). These
results indicate that the fusion of GFP to PKD has no detect-
able e¡ect on the basal catalytic activity, phorbol ester bind-
ing and kinase activation of PKD.
3.2. Phorbol ester treatment induces the translocation of
GFP-PKD to the plasma membrane of RBL 2H3 cells
As these experiments demonstrated that GFP-PKD was
functional, we next examined whether GFP-PKD, transiently
transfected into the mast cell line RBL 2H3, undergoes trans-
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location in response to PDB. The confocal images illustrated
in Fig. 2A show that both GFP-PKD and GFP-PKD vCRD
(shown in green) are expressed throughout the cytosol and are
excluded from the nuclei (shown in red) of resting RBL 2H3
cells, as shown by the overlay of the images. Treatment with
PDB resulted in a striking translocation of GFP-PKD from
the cytosol to the plasma membrane (Fig. 2A, upper panels).
After 15 min stimulation with PDB, 85 þ 5% of the cells
(n = 3) show plasma membrane localization of GFP-PKD.
This plasma membrane localization of GFP-PKD was main-
tained for at least 3 h in the continued presence of PDB
(results not shown). In contrast, phorbol ester treatment had
no e¡ect on the cytosolic localization of GFP-PKD vCRD
(Fig. 2A, lower panels). This mutant remained in the cytosol
in 95 þ 1.5% (n = 3) of PDB-treated RBL 2H3 cells, even 1 h
after treatment (results not shown).
GFP-PKD translocation in response to PDB could also be
demonstrated by biochemical fractionation of transiently
transfected RBL 2H3 cells, i.e. when cytosolic and membrane
fractions from resting and PDB-stimulated cells were pre-
pared. Western blotting with an anti-GFP antibody revealed
that PDB induced the translocation of GFP-PKD from cyto-
solic to membrane fractions (Fig. 2B). Again, no phorbol
ester-mediated translocation of the GFP-PKD vCRD mutant
was detected (Fig. 2B). Thus, phorbol ester binding to the
CRD of PKD induces the translocation of PKD to the plasma
membrane.
3.3. PKD activation is dissociatable from PKD translocation
The two cysteine-rich motifs (cys1 and cys2) within the
CRD of PKD are not functionally equivalent, with cys2 act-
ing as the major phorbol ester binding site both in vitro and
in vivo [11]. In fact, phorbol ester binding to PKD is greatly
reduced by a single amino acid substitution (P287G) within
the cys2 motif [11]. In the present study, we utilized this mu-
tant (PKD P287G) to determine whether PKD translocation
to the plasma membrane is required for PKC-mediated PKD
activation.
Living RBL 2H3 cells, transiently transfected with GFP-
PKD or GFP-PKD P287G, were imaged before and during
stimulation with 200 nM PDB to visualize PKD re-distribu-
tion in real time. Translocation of GFP-PKD from the cytosol
Fig. 1. Expression, activation and phorbol ester binding of GFP-PKD. (A) (upper) Schematic representation of GFP-PKD WT and a PKD de-
letion mutant lacking the CRD (GFP-PKD vCRD), fused to the C-terminus of GFP. Lower: anti-GFP and anti-PKD Western blots of COS-7
and RBL 2H3 cells transfected with the GFP-PKD constructs are shown. Endogenous PKD present in RBL 2H3 cells is indicated by an ar-
row. Molecular weight markers are indicated. (B) In vitro kinase assays of WT PKD and GFP-PKD expressed in COS-7 cells, either left unsti-
mulated (3) or treated with 200 nM PDB for 15 min (+). PKD activity was measured by autophosphorylation as described under Section 2.
Western blots (with anti-GFP and anti-PKD antibodies) are shown below to con¢rm equal expression levels of the two PKD constructs. (C)
Total (black columns) and non-speci¢c (open columns) binding of [3H]PDB to COS-7 cells expressing vector alone, GFP-PKD, GFP-PKD
vCRD, PKD or PKD vCRD. Data are the mean þ S.E.M. of two independent experiments, each carried out in duplicate, and are expressed as
the fold increase over background.
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to the plasma membrane and to vesicle-like structures within
the cytosol was detectable within 5 min after the addition of
PDB and maximal PKD re-distribution was seen after 15 min
(Fig. 3A, upper panels). In contrast, addition of PDB did not
induce any signi¢cant changes in the subcellular localization
of GFP-PKD P287G over the same time period (Fig. 3A,
lower panels).
To determine whether PKD translocation is necessary for
PKD activation, we measured the kinetics of PDB-mediated
activation of both GFP-PKD and GFP-PKD P287G in RBL
Fig. 2. Translocation of GFP-PKD and GFP-PKD vCRD in RBL 2H3 cells. (A) Confocal images of paraformaldehyde-¢xed, transfected RBL
2H3 cells expressing GFP-PKD WT and GFP-PKD vCRD, stimulated with (PDB) or without (3) 200 nM PDB for 15 min. GFP is shown in
green and nuclei are shown counterstained with propidium iodide (red). Results are representatives of three independent experiments. (B) Bio-
chemical fractionation of RBL 2H3 cells expressing GFP-PKD WT and GFP-PKD vCRD, stimulated with (+) or without (3) 200 nM PDB
for 15 min. Cytosolic (C) and membrane (M) fractions were prepared as described under Section 2 and Western-blotted with an anti-GFP anti-
body. Identical results were obtained in two independent experiments.
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2H3 cells, in parallel experiments. Lysates of cells treated with
200 nM PDB for various times were immunoprecipitated with
an antibody directed against the COOH-terminal region of
PKD. The resulting immune complexes were incubated with
[Q-32P]ATP and analyzed by SDS-PAGE and autoradiography
to determine the level of enzyme autophosphorylation. As
shown in Fig. 3B, the time-courses of GFP-PKD and GFP-
PKD P287G activation were identical. Interestingly, the acti-
vation of GFP-PKD, which was evident as early as within
1 min of treatment with PDB, preceded its translocation to
the plasma membrane, providing further evidence that PKD
activation is not dependent on PKD translocation.
3.4. PKC-dependent activation of both PKD WT and PKD
P287G in intact COS-7 cells
To substantiate the conclusions obtained with the GFP-
PKD chimeric proteins, we also examined PDB-induced acti-
vation and translocation of PKD and PKD P287G expressed
in COS-7 cells. As illustrated in Fig. 4, the PDB dose-response
curves for the activation of PKD and PKD P287G were iden-
tical, as shown both by autophosphorylation (Fig. 4A) and by
exogenous substrate (syntide-2) phosphorylation (Fig. 4B). In
striking contrast, the PDB dose-response curves for the trans-
location of WT PKD and PKD P287G (measured by bio-
chemical fractionation) were clearly di¡erent (Fig. 4C). For
example, at a concentration of 0.2 WM PDB, both WT PKD
and PKD P287G were activated to the same extent and more
than 95% of WT PKD had translocated from the cytosolic
fraction. However, less than 10% of PKD P287G had trans-
located from the cytosol at this concentration of PDB. These
results further substantiate that CRD-dependent translocation
of PKD to the plasma membrane is not required for PKD
activation.
Since the conclusion that PKC-dependent PKD activation
and membrane translocation are separate events relies on the
results obtained with PKD P287G, we veri¢ed that the acti-
vation of this PKD mutant in response to PDB is, in fact,
mediated by PKC, as has previously been demonstrated with
WT PKD. As shown in Fig. 5A, pretreatment with GF
109303X or Ro 31-8220, speci¢c PKC inhibitors with no di-
rect action on PKD [12,14,16], dramatically inhibited PDB-
induced activation of either WT PKD or PKD P287G, both
in COS-7 cells and in RBL 2H3 cells, indicating that PKD
P287G like WT PKD requires functional PKC isoforms for its
activation. Furthermore, co-transfection of PKD or PKD
P287G together with constitutively activated PKCO* or R*
Fig. 3. Dissociation of PKD activation and translocation in RBL 2H3 cells. (A) RBL 2H3 cells, expressing GFP-PKD WT (upper) and GFP-
PKD P287G (lower) were stimulated with 200 nM PDB, up to 15 min. Cells were maintained at 37‡C and confocal images were taken every
30 s. Similar results were obtained in four independent experiments. (B) RBL 2H3 cells expressing GFP-PKD WT and GFP-PKD P287G were
left unstimulated (3) or were treated with 200 nM PDB for increasing periods of time (1^10 min). In vitro kinase assays were performed and
PKD activity was measured by autophosphorylation. Data are representatives of two independent experiments.
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isoforms was su⁄cient to induce activation of both PKD
forms in RBL 2H3 cells (Fig. 5B). This activation was only
slightly further increased by treatment of the intact cells with
PDB. No such increases in the basal activity of WT or P287G
mutant PKD were detected when they were co-transfected
with vector alone, although they could be activated by treat-
ment with PDB (Fig. 5B). Thus, activation of PKD P287G,
like WT PKD, occurs through a PKC-dependent signal trans-
duction pathway.
4. Discussion
Protein targeting to speci¢c cellular locations as the result
of increases in lipid second messengers or the activation of
adaptor molecules has become a recognized mechanism for
regulating complex signaling cascades [27^29]. In the present
study, we used visualization of GFP-PKD chimeras to dem-
onstrate that treatment with phorbol ester induces a striking
translocation of PKD from the cytosol to the plasma mem-
brane. PDB-induced translocation was completely prevented
by deletion of the CRD and severely impaired by a single
amino acid substitution in the second cysteine-rich motif of
the CRD, in agreement with recent results demonstrating that
this motif is responsible for mediating PDB binding to PKD
[11].
Previous results demonstrated that PKD is activated by
phosphorylation through a novel PKC-dependent signal
transduction pathway in vivo [12,14,16]. More recently, the
residues Ser-744 and Ser-748 in the activation loop of PKD
have been identi¢ed as critical activating phosphorylation sites
[18]. Here, we examined whether direct phorbol ester binding
to PKD CRD leading to its membrane translocation is neces-
sary for PKC-dependent activation. A salient feature of the
results presented here is that PKD activation could be clearly
dissociated from its membrane translocation. Speci¢cally, a
single amino acid substitution in the second cysteine-rich mo-
tif of PKD (P287G) greatly impaired PDB-induced membrane
translocation but did not a¡ect PDB-induced PKD activation.
In addition, kinetic analysis revealed that phorbol ester-medi-
ated PKD activation preceded its membrane translocation.
Our results support a model in which direct binding of phor-
bol esters to PKD leading to its membrane translocation is
not required for PKC-dependent PKD activation.
An important implication of the results presented here is
that the regulation of PKD can be distinguished from that of
other signal transducing protein kinases that undergo second
messenger-regulated intracellular translocation. For example,
Akt/PKB translocates to the plasma membrane in response to
signal-dependent production of PtdIns(3,4)P2 and PtdIns-
(3,4,5)P3 and is only then phosphorylated and activated by
two separate phosphoinositide-dependent protein kinases (re-
viewed in [28]). Similarly, Raf requires Ras-GTP-mediated
Fig. 4. PKD activation is dissociatable from its translocation in COS-7 cells. (A and B) In vitro kinase assays of PKD WT and PKD P287G
expressed in COS-7 cells, after stimulation with increasing concentrations of PDB (0^2 WM) for 15 min. PKD activity was measured either by
autophosphorylation (A) or by exogenous substrate (syntide-2) phosphorylation (B). (C) COS-7 cells expressing PKD WT and PKD P287G
were stimulated with various concentrations of PDB (0^2 WM) for 15 min, as indicated. Cytosolic fractions were prepared as described previ-
ously and Western blotted with an anti-PKD antibody (left). Blots were quantitated by densitometry and the results expressed as the percentage
of cytosolic PKD levels in control untreated cells (right). All results shown are representatives of three individual experiments.
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membrane translocation for activation [30,31]. In these cases,
translocation is an obligatory step that precedes enzyme acti-
vation. In contrast to these signal-regulated protein kinases,
we conclude that PKD translocation and activation are dis-
tinct processes that operate in parallel to regulate the activity
and localization of this enzyme in intact cells.
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Fig. 5. PKD P287G, like PKD, is activated via PKC in vivo. (A)
PKD WT and PKD P287G constructs were expressed either in
COS-7 cells (upper) or in RBL 2H3 cells (lower). Cells were left un-
treated (3) or were pretreated (+) with the PKC-speci¢c inhibitors,
GF 109203X (3.5 WM) or Ro 31-8220 (2.5 WM), for 1 h, as indi-
cated. Cells were subsequently left unstimulated (3) or were treated
with 200 nM PDB for 15 min (+) and PKD activity was measured
using in vitro kinase assays. (B) RBL 2H3 cells were co-transfected
with either vector control, PKCR* or PKCO* constructs in the pres-
ence of either PKD WT or PKD P287G, as indicated. Cells were
then left unstimulated (3) or were treated with 200 nM PDB for
10 min (+) and PKD activity was determined using in vitro kinase
assays. Data are representatives of two independent experiments.
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